POY_1170x120_8-12-19

Allergan

AbbVie to acquire Allergan

AbbVie to acquire Allergan

NORTH CHICAGO, Ill. — AbbVie  and Allergan announced that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion, based on the closing price of AbbVie’s common stock of $78.45 on June 24, 2019. (PRNewsfoto/AbbVie) “This is a

Allergan unveils new digital hub Spotlyte

Allergan unveils new digital hub Spotlyte

DUBLIN — Allergan announced the launch of Spotlyte – an innovative digital hub of curated content that helps consumers discover how medical aesthetic treatments may fit into their routines. Through well-researched content, product reviews and insider profiles, together with the latest beauty news and trends, the site functions as a holistic and informative lens into these worlds.

Allergan COO to become Amneal CEO

Allergan COO to become Amneal CEO

NEW YORK — Merger partners Amneal Pharmaceuticals LLC and Impax Laboratories Inc. have tabbed Robert Stewart, executive vice president and chief operating officer of Allergan plc, to lead the combined company. Plans call for Stewart to join Amneal as president effective Jan. 25. After Amneal and Impax finalize their merger, announced in mid-October, he will

Allergan aims to raise IBS-D awareness

Allergan aims to raise IBS-D awareness

DUBLIN, Ireland — Allergan plc has teamed up with the American Gastroenterological Association (AGA) to launch Toilet Talk, a campaign to help raise awareness about irritable bowel syndrome with diarrhea (IBS-D). The Toilet Talk campaign, in recognition of IBS Awareness Month, aims to reduce the stigma associated with talking about bowel health and urges people

Allergan readies launch of Rhofade rosacea cream

Allergan readies launch of Rhofade rosacea cream

DUBLIN, Ireland — Allergan plc is set to release Rhofade oxymetazoline hydrochloride cream 1%, a topical medication to help treat rosacea. Indicated for persistent facial erythema, or redness, associated with rosacea in adults, Rhofade adds brings a once-daily solution to the few alternatives available for the treatment of this rosacea symptom, Allergan said. Plans call

Allergan announces pair of biopharma acquisitions

Allergan announces pair of biopharma acquisitions

DUBLIN, Ireland — Chalk up three acquisitions for Allergan plc in less than a week. On Tuesday, Allergan said it plans to purchase clinical-stage biopharmaceutical company Tobira Therapeutics Inc. in an agreement valued at up to $1.695 billion. South San Francisco-based Tobira focuses on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and

Allergan to acquire Vitae Pharmaceuticals

Allergan to acquire Vitae Pharmaceuticals

DUBLIN, Ireland — Allergan plc plans to buy clinical-stage biotech firm Vitae Pharmaceuticals Inc. in a cash deal valued at $639 million. Allergan said the acquisition will bolster its dermatology product pipeline with the addition of VTP-43742, a Phase 2 orally active RORγt inhibitor for the potential treatment of psoriasis and other autoimmune disorders. The

Allergan sells Anda to Teva for $500 million

Allergan sells Anda to Teva for $500 million

NEW YORK — Another large deal has been struck between Allergan plc and Teva Pharmaceutical Industries Ltd. The companies on Wednesday announced the sale of Allergan’s Anda Inc. distribution business to Teva for $500 million. That came a day after they reported the close of Teva’s $39 billion acquisition of the Allergan’s legacy Actavis generics

Mayne Pharma closes $625 million generics buy

Mayne Pharma closes $625 million generics buy

GREENVILLE, N.C. — Mayne Pharma has completed its purchase of a package of generic drug products from Teva Pharmaceutical Industries Ltd. and Allergan plc. Mayne said Wednesday that under the $652 million deal, announced in late June, it takes ownership of 37 approved and five filed generic pharmaceutical products. The transaction was the largest generics

Teva, Allergan complete $39 billion generics deal

Teva, Allergan complete $39 billion generics deal

NEW YORK — Teva Pharmaceutical Industries Ltd. has closed its acquisition of the Allergan plc generics business. The companies said Tuesday that under the deal, announced last July, Allergan receives $33.4 billion in cash and 100.3 million shares of Teva stock, valued at $5.4 billion based on the opening price of $53.39 for Teva shares

FTC clears Teva-Allergan, Mylan-Meda acquisitions

FTC clears Teva-Allergan, Mylan-Meda acquisitions

NEW YORK — The Federal Trade Commission has given its approval to two major pharma acquisitions: Teva Pharmaceutical Industries Ltd.’s $40 billion deal to buy Allergan plc’s generics business and Mylan N.V.’s $9.9 billion deal to acquire Meda AB. Teva said that with the FTC’s acceptance of the proposed consent order, the company has satisfied

Impax to acquire generics from Teva, Allergan

Impax to acquire generics from Teva, Allergan

HAYWARD, Calif. — Impax Laboratories Inc. has agreed to buy a portfolio of generic drug products from Teva Pharmaceutical Industries Ltd. and affiliates of Allergan plc for $586 million. Impax said Tuesday that the purchase — covering solid oral, inhalable, injectable and topical dosage forms — includes a group of 15 currently marketed generic products;

Dr. Reddy’s to acquire ANDAs from Teva, Allergan

Dr. Reddy’s to acquire ANDAs from Teva, Allergan

HYDERABAD, India, and PRINCETON, N.J. — Dr. Reddy’s Laboratories plans to buy eight Abbreviated New Drug Applications (ANDAs) in the United States from Teva Pharmaceutical Industries Ltd. and an affiliate of Allergan plc for $350 million in cash. Dr. Reddy’s, which announced the agreement over the weekend, said the acquired products are being divested by

Allergan partners with Bosworth to launch Aczone Gel

Allergan partners with Bosworth to launch Aczone Gel

DUBLIN, Ireland — Allergan plc has teamed up with actress and model Kate Bosworth to launch Aczone Gel 7.5%, a new prescription topical treatment for acne. Also on Monday, Allergan said it has received Food and Drug Administration approval for Byvalson tablets (nebivolol 5 mg/valsartan 80 mg), a hypertension treatment that the company called the